10% hike too little, we want more to offset GST impact, say pharma players

Also want 100% input tax credit against 40% in cases where dealers don't have receipts for stocks

pharma, pharma industry
Govt proposes to bring fixed-dose combinations under price control
Veena Mani New Delhi
Last Updated : Jun 13 2017 | 1:39 AM IST
The pharmaceutical industry has sought permission to increase prices of non-scheduled drugs by more than the stipulated 10 per cent in a year, as the tax rate on most drugs was raised to 12 per cent under the proposed GST regime from the current nine per cent.

In a meeting held by the Department of Pharmaceuticals with the drug industry, pharma representatives raised this issue.

As per the Drug Price Control Order (DPCO) 2013, pharmaceutical companies can increase the price of non-scheduled drugs by upto 10 per cent each year.

While 80 per cent of drugs have been put under the 12 per cent GST rate, essential drugs are in the 5 per cent bracket.

The industry also raised the issue of refunds on taxes paid on input, called input tax credit in technical jargon. The GST Council has decided that for stocks whose receipts are not available with dealers, only 40 per cent input tax credit will be given. However, the industry wanted 100 per cent refund.

An industry representative who attended the meeting told Business Standard, "We also raised the issue of input tax credit with the department. The input tax credit which is 40 per cent should be made 100 per cent."

The pharma representatives also stated that the department emphasised on adequate stock in the market. This cames at a time when there has been reduction in inventory from 40 days to 27 days at stockist level on an average, according to All India Organisation of Chemists and Druggists (AIOCD).

Representatives of top pharmaceutical companies said stockists are not willing to keep high levels of inventory, fearing they will have to send back their stock if relabelling is required. Meanwhile, pharmaceutical companies are even willing to compensate the stockists for the losses they are likely to make due to GST. It is estimated that the impact of GST will be felt in the coming two quarters.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story